Informations générales (source: ClinicalTrials.gov)
Cohort of Patients Presenting Unexplained Recurrent Miscarriages and Identification of Early Miscarriage Recidivism Factors
Observational
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
octobre 2022
octobre 2025
27 août 2025
About 1 to 3% of women of childbearing age have repeated early spontaneous miscarriages
(RCF) defined by at least 3 fetal losses before 14 weeks of gestation. RCFs may be
related to parental chromosomal abnormalities, congenital or acquired uterine
abnormalities, hormonal causes (e.g. type 1 and 2 diabetes, ovarian failure), infectious
etiology, constitutional or acquired thrombophilia or sickle cell disease.
The presence of antiphospholipid antibodies, antithyroid and anti-transglutaminase
antibodies in approximately 10% of cases suggests an autoimmune origin for these fetal
losses. The role of other antibodies, in particular unconventional antiphospholipid
antibodies, remains to be established. Indeed half of RCF cases would be due to an
immunological dysregulation of the mother leading to a decrease in tolerance to the
fetus. Several studies have shown immune abnormalities, such as an imbalance of pro and
anti-inflammatory cytokines, an increase in cytotoxic cells and a defect in regulatory
cells in the blood of patients. The assessment of these immune abnormalities is not
currently carried out routinely in France in women with recurrent early miscarriages.
When one of these known causes is excluded, it is unexplained RCF which represents 50% of
RCF. In these women with unexplained RCF, slightly more than half could be linked to
aneuploidies and primary recurrent spontaneous abortions. The evaluation of the degree of
aneuploidy and the genetic origin of fetal losses remains difficult, the examination of
the sample of tissue from the miscarriage being rarely available, due to the spontaneous
nature of the loss.
The constitution of a prospective cohort of patients with RCF is an essential step in
exploring the factors associated with the success of treatment.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CH DE MELUN SITE SANTEPOLE | MEKINIAN Arsene | 18/09/2025 17:34:26 | Contacter | ||
| AP-HP Assistance publique - Hôpitaux de Paris | 18/09/2025 17:34:26 | Contacter | |||
| AP-HP - Hôpital Antoine Béclère | |||||
| AP-HP - Hôpital Armand Trousseau-La Roche Guyon | |||||
| AP-HP - Hôpital Jean Verdier | |||||
| AP-HP - Hôpital Robert Debré | |||||
| AP-HP - Hôpital Saint Antoine | |||||
| AP-HP - Hôpital Tenon | |||||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| 18/09/2025 17:34:25 | Contact (sur clinicalTrials) | ||||
| 18/09/2025 17:34:25 | Contact (sur clinicalTrials) | ||||
| 18/09/2025 17:34:25 | Contact (sur clinicalTrials) | ||||
| 18/09/2025 17:34:25 | Contact (sur clinicalTrials) | ||||
| 18/09/2025 17:34:25 | Contact (sur clinicalTrials) | ||||
| 18/09/2025 17:34:25 | Contact (sur clinicalTrials) | ||||
| 18/09/2025 17:34:26 | Contact (sur clinicalTrials) | ||||
Critères
Femme
Inclusion Criteria:
- Age 18 to 50 years
- Patients with at least 3 recurrent miscarriages
- Signed consent form
- Age 18 to 50 years
- Patients with at least 3 recurrent miscarriages
- Signed consent form
- Patients who don't accept the use of their data